What is Sidoti’s Forecast for PRE Q2 Earnings?

Prenetics Global Limited (NASDAQ:PRE) – Research analysts at Sidoti issued their Q2 2026 earnings per share estimates for Prenetics Global in a research report issued to clients and investors on Monday, June 22nd. Sidoti analyst A. Hantman expects that the company will earn ($0.91) per share for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.03) per share. Sidoti also issued estimates for Prenetics Global’s FY2026 earnings at ($2.12) EPS.

Several other equities research analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research report on Tuesday, April 21st. Benchmark assumed coverage on Prenetics Global in a report on Tuesday, June 16th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Lake Street Capital initiated coverage on Prenetics Global in a research note on Monday, March 16th. They issued a “buy” rating and a $29.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.75.

Prenetics Global Trading Down 1.0%

PRE opened at $19.72 on Thursday. Prenetics Global has a 1-year low of $7.18 and a 1-year high of $23.63. The company has a market cap of $332.68 million, a price-to-earnings ratio of -4.31 and a beta of 0.24. The company’s fifty day moving average price is $18.44 and its two-hundred day moving average price is $18.21.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.07). The business had revenue of $35.95 million during the quarter, compared to analyst estimates of $36.00 million. Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%.

Prenetics Global declared that its Board of Directors has authorized a share repurchase program on Friday, March 6th that allows the company to repurchase $40.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 15.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of Prenetics Global

Several institutional investors have recently made changes to their positions in the company. 683 Capital Management LLC bought a new position in shares of Prenetics Global during the fourth quarter valued at about $1,181,000. Manatuck Hill Partners LLC bought a new stake in Prenetics Global in the 4th quarter worth about $170,000. T3 Companies LLC bought a new stake in Prenetics Global in the 4th quarter worth about $170,000. Stevens Capital Partners increased its stake in Prenetics Global by 4.7% in the 4th quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock valued at $287,000 after buying an additional 825 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Prenetics Global during the 4th quarter worth approximately $810,000. Institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.